Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ke Shang

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Pharmacological Research|February 21, 2025
Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASHJianhua Zhang, Xujie Liu, Xian Jin, et al.
Journal of Pharmacological Sciences|July 31, 2014
Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patientShun-Bin Luo, Chuan-Bao Li, Da-Peng Dai, et al.
Redox Biology|December 24, 2024
Microglial Nrf2-mediated lipid and iron metabolism reprogramming promotes remyelination during white matter ischemiaHang Zhang, Sheng Yang, Yi-Lin Lu, et al.
EMBO Molecular Medicine|February 27, 2024
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravisDai-Shi Tian, Chuan Qin, Ming-Hao Dong, et al.
Translational Psychiatry|June 25, 2025
Identification of novel therapeutic targets for cognitive performance and associations with brain healthLu-Yang Zhang, Yu-Xin Liu, Yun-Hui Chu, et al.
The Journal of Clinical Investigation|March 2, 2026
Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74/CXCR4 and interferon signalingSheng Yang, Hang Zhang, Lu-Lu Xu, et al.
Cell Reports|June 10, 2026
Bilirubin mitigates ischemic white matter injury by targeting transferrin-receptor-mediated B cell immunometabolismLian Chen, Xiao-Wei Pang, Zhi-Cheng Mei, et al.
Med (New York, N.Y.)|May 27, 2025
Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathyMing-Hao Dong, Zhi-Cheng Mei, Luo-Qi Zhou, et al.
Signal Transduction and Targeted Therapy|January 3, 2023
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim resultsChuan Qin, Dai-Shi Tian, Luo-Qi Zhou, et al.
Cell|October 16, 2025
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosisChuan Qin, Ming-Hao Dong, Luo-Qi Zhou, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Pharmacological Research|February 21, 2025
Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASHJianhua Zhang, Xujie Liu, Xian Jin, et al.
Journal of Pharmacological Sciences|July 31, 2014
Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patientShun-Bin Luo, Chuan-Bao Li, Da-Peng Dai, et al.
Redox Biology|December 24, 2024
Microglial Nrf2-mediated lipid and iron metabolism reprogramming promotes remyelination during white matter ischemiaHang Zhang, Sheng Yang, Yi-Lin Lu, et al.
EMBO Molecular Medicine|February 27, 2024
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravisDai-Shi Tian, Chuan Qin, Ming-Hao Dong, et al.
Translational Psychiatry|June 25, 2025
Identification of novel therapeutic targets for cognitive performance and associations with brain healthLu-Yang Zhang, Yu-Xin Liu, Yun-Hui Chu, et al.
The Journal of Clinical Investigation|March 2, 2026
Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74/CXCR4 and interferon signalingSheng Yang, Hang Zhang, Lu-Lu Xu, et al.
Cell Reports|June 10, 2026
Bilirubin mitigates ischemic white matter injury by targeting transferrin-receptor-mediated B cell immunometabolismLian Chen, Xiao-Wei Pang, Zhi-Cheng Mei, et al.
Med (New York, N.Y.)|May 27, 2025
Anti-BCMA CAR-T cell therapy in relapsed/refractory chronic inflammatory demyelinating polyneuropathyMing-Hao Dong, Zhi-Cheng Mei, Luo-Qi Zhou, et al.
Signal Transduction and Targeted Therapy|January 3, 2023
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim resultsChuan Qin, Dai-Shi Tian, Luo-Qi Zhou, et al.
Cell|October 16, 2025
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosisChuan Qin, Ming-Hao Dong, Luo-Qi Zhou, et al.
Pageof 18